Online inquiry

IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4362MR)

This product GTTS-WQ4362MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD80&CD86 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005191.4; NM_001206924.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 941; 942
UniProt ID A0N0P2; P42081
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4362MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7844MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ4870MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ8308MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ2916MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ5383MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ5863MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ13938MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ15275MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Theraloc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW